Enanta Pharmaceuticals Company Profile (NASDAQ:ENTA)

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ENTA
  • CUSIP: N/A
  • Web: www.enanta.com
Capitalization:
  • Market Cap: $911.57 million
  • Outstanding Shares: 19,090,000
Average Prices:
  • 50 Day Moving Avg: $45.34
  • 200 Day Moving Avg: $37.22
  • 52 Week Range: $22.17 - $49.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -49.79
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $39.73 million
  • Price / Sales: 22.73
  • Book Value: $13.66 per share
  • Price / Book: 3.46
Profitability:
  • EBITDA: ($30,750,000.00)
  • Net Margins: -51.85%
  • Return on Equity: -7.74%
  • Return on Assets: -7.39%
Debt:
  • Current Ratio: 18.53%
  • Quick Ratio: 18.54%
Misc:
  • Average Volume: 175,470 shs.
  • Beta: 0.65
  • Short Ratio: 5.57
 

Frequently Asked Questions for Enanta Pharmaceuticals (NASDAQ:ENTA)

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.44) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.05. The firm had revenue of $7.51 million for the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The business's quarterly revenue was down 46.3% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.06) earnings per share. View Enanta Pharmaceuticals' Earnings History.

When will Enanta Pharmaceuticals make its next earnings announcement?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, November, 20th 2017. View Earnings Estimates for Enanta Pharmaceuticals.

Where is Enanta Pharmaceuticals' stock going? Where will Enanta Pharmaceuticals' stock price be in 2017?

4 brokerages have issued 1 year price targets for Enanta Pharmaceuticals' shares. Their predictions range from $36.00 to $53.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $42.33 in the next year. View Analyst Ratings for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:

  • Bruce L.A. Carter Ph.D., Chairman of the Board,Independent Director
  • Jay R. Luly Ph.D., President, Chief Executive Officer, Director
  • Paul J. Mellett Jr., Chief Financial Officer, Senior Vice President - Finance & Administration
  • Yat Sun Sun Or Ph.D., Senior Vice President - Research & Development, Chief Scientific Officer
  • Nathaniel S. Gardiner J.D., Senior Vice President, General Counsel
  • Nathalie Adda M.D., Senior Vice President and Chief Medical Officer
  • Timothy D. Ocain Ph.D., Senior Vice President - New Product Strategy and Development
  • Kristine Peterson, Director
  • Ernst-Gunter Afting M.D., Ph.D.,, Independent Director
  • Stephen Buckley Jr., Independent Director

Who owns Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Eqis Capital Management Inc. (0.16%). Company insiders that own Enanta Pharmaceuticals stock include Nathaniel S Gardiner, Paul J Mellett, Terry Vance and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

Who sold Enanta Pharmaceuticals stock? Who is selling Enanta Pharmaceuticals stock?

Enanta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. View Insider Buying and Selling for Enanta Pharmaceuticals.

How do I buy Enanta Pharmaceuticals stock?

Shares of Enanta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of Enanta Pharmaceuticals stock can currently be purchased for approximately $47.30.


MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Enanta Pharmaceuticals (NASDAQ:ENTA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $42.33 (10.50% downside)
Consensus Price Target History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Price Target History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Analysts' Ratings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/4/2017JMP SecuritiesBoost Price Target$40.00 -> $53.00LowView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> OutperformHighView Rating Details
8/9/2017J P Morgan Chase & CoReiterated RatingOverweight$32.00 -> $38.00LowView Rating Details
8/8/2017Robert W. BairdBoost Price TargetNeutral$27.00 -> $36.00MediumView Rating Details
2/9/2016Barclays PLCBoost Price TargetUnderweight$16.00 -> $18.00N/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Earnings by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Earnings History by Quarter for Enanta Pharmaceuticals (NASDAQ ENTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/20/2017$1.88N/AView Earnings Details
8/7/2017Q3 2017($0.49)($0.44)$8.08 million$7.51 millionViewListenView Earnings Details
5/8/2017Q2 2017($0.38)($0.28)$9.19 million$9.00 millionViewListenView Earnings Details
2/8/2017Q117($0.18)($0.26)$12.70 million$11.90 millionViewListenView Earnings Details
11/21/2016Q416($0.11)($0.09)$13.56 million$12.80 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.06)$13.07 million$14.00 millionViewListenView Earnings Details
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details
8/11/2014Q314$1.65$1.81$40.83 million$42.10 millionViewN/AView Earnings Details
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details
2/13/2014Q114($0.15)($0.30)$1.41 million$0.89 millionViewN/AView Earnings Details
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enanta Pharmaceuticals (NASDAQ:ENTA)
Current Year EPS Consensus Estimate: $0.97 EPS
Next Year EPS Consensus Estimate: $-0.95 EPS

Dividends

Dividend History for Enanta Pharmaceuticals (NASDAQ:ENTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Insider Ownership Percentage: 9.28%
Institutional Ownership Percentage: 66.06%
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Insider Trades by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Yat Sun OrInsiderSell13,921$35.09$488,487.89View SEC Filing  
11/29/2016Yat Sun OrInsiderSell13,921$31.44$437,676.24View SEC Filing  
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.00View SEC Filing  
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.00View SEC Filing  
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.00View SEC Filing  
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.00View SEC Filing  
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.00View SEC Filing  
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00View SEC Filing  
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00View SEC Filing  
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00View SEC Filing  
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00View SEC Filing  
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00View SEC Filing  
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Enanta Pharmaceuticals (NASDAQ:ENTA)
Latest Headlines for Enanta Pharmaceuticals (NASDAQ:ENTA)
Source:
DateHeadline
finance.yahoo.com logoEdited Transcript of ENTA earnings conference call or presentation 8-May-17 8:30pm GMT
finance.yahoo.com - October 17 at 7:06 PM
finance.yahoo.com logoIs There Now An Opportunity In Enanta Pharmaceuticals Inc (ENTA)?
finance.yahoo.com - October 12 at 7:09 PM
finance.yahoo.com logoEnanta Announces Data to be Presented on AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) at The Liver Meeting® 2017
finance.yahoo.com - October 11 at 7:53 PM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - October 10 at 7:40 PM
americanbankingnews.com logoEnanta Pharmaceuticals (ENTA) versus Its Rivals Critical Comparison
www.americanbankingnews.com - October 9 at 8:10 AM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) PT Raised to $53.00 at JMP Securities
www.americanbankingnews.com - October 8 at 6:40 PM
finance.yahoo.com logoETFs with exposure to Enanta Pharmaceuticals, Inc. : October 4, 2017
finance.yahoo.com - October 4 at 5:05 PM
seekingalpha.com logoEnanta Pharma (ENTA) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 29 at 2:52 PM
businesswire.com logoEnanta Announces that AbbVie’s MAVIRET™ (glecaprevir/pibrentasvir) Received Approval in Japan for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C
www.businesswire.com - September 27 at 11:34 PM
seekingalpha.com logoEnanta Pharma (ENTA) Presents At Cambridge Healthtech Institute's 15th Annual Discovery On Target - Slideshow
seekingalpha.com - September 27 at 11:34 PM
americanbankingnews.com logoReviewing Enanta Pharmaceuticals (ENTA) and The Competition
www.americanbankingnews.com - September 25 at 2:18 PM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 24 at 1:16 PM
finance.yahoo.com logoETFs with exposure to Enanta Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 6:15 PM
finance.yahoo.com logoEnanta Pharmaceuticals, Inc. :ENTA-US: Earnings Analysis: Q3, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 6:09 PM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) Coverage Initiated at Royal Bank Of Canada
www.americanbankingnews.com - September 14 at 11:06 PM
finance.yahoo.com logoEnanta Pharmaceuticals Announces the Appointment of Kristine Peterson to Its Board of Directors
finance.yahoo.com - September 13 at 7:40 PM
americanbankingnews.com logoEnanta Pharmaceuticals (ENTA) versus Global Blood Therapeutics (GBT) Head-To-Head Analysis
www.americanbankingnews.com - September 8 at 12:30 PM
americanbankingnews.com logoNabriva Therapeutics AG (NBRV) vs. Enanta Pharmaceuticals (ENTA) Critical Contrast
www.americanbankingnews.com - September 5 at 10:22 AM
finance.yahoo.com logoEnanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
finance.yahoo.com - August 30 at 7:35 PM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 30 at 1:00 PM
finance.yahoo.com logoEnanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session
finance.yahoo.com - August 28 at 6:05 PM
americanbankingnews.com logo$72.75 Million in Sales Expected for Enanta Pharmaceuticals, Inc. (ENTA) This Quarter
www.americanbankingnews.com - August 25 at 6:00 AM
finance.yahoo.com logoSurging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)
finance.yahoo.com - August 23 at 10:42 PM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) Expected to Announce Earnings of $1.94 Per Share
www.americanbankingnews.com - August 23 at 2:16 PM
americanbankingnews.com logoHead-To-Head Survey: Enanta Pharmaceuticals (ENTA) versus Codexis (CDXS)
www.americanbankingnews.com - August 21 at 10:22 PM
americanbankingnews.com logoJ P Morgan Chase & Co Reiterates "Overweight" Rating for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
www.americanbankingnews.com - August 10 at 12:22 AM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS
www.americanbankingnews.com - August 8 at 12:46 PM
finance.yahoo.com logoEdited Transcript of ENTA earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 4:39 AM
finance.yahoo.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2017
finance.yahoo.com - August 7 at 6:34 PM
finance.yahoo.com logoEnanta Pharmaceuticals reports 3Q loss
finance.yahoo.com - August 7 at 6:34 PM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) Expected to Announce Quarterly Sales of $8.12 Million
www.americanbankingnews.com - August 7 at 9:12 AM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (ENTA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 5 at 1:06 PM
streetinsider.com logoEnanta Pharma (ENTA) Sees Receiving $40M Milestone Following FDA Approval of AbbVie's MAVYRET
www.streetinsider.com - August 3 at 4:59 PM
finance.yahoo.com logoEnanta Announces U.S. FDA Approval of AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in as Little as 8 Weeks
finance.yahoo.com - August 3 at 4:59 PM
finance.yahoo.com logoFeatured Company News – EC Grants AbbVie's MAVIRET Marketing Authorization for Treatment of Chronic Hepatitis C
finance.yahoo.com - August 1 at 6:57 PM
streetinsider.com logoEnanta (ENTA) Announce EC Grants AbbVie (ABBV) MAA for MAVIRet for Treatment of Chronic Hepatitis C in All Major Genotypes
www.streetinsider.com - July 29 at 5:28 PM
businesswire.com logoEnanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major ...
www.businesswire.com - July 28 at 8:23 PM
finance.yahoo.com logoEnanta Announces European Commission Grants AbbVie Marketing Authorization for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
finance.yahoo.com - July 28 at 8:23 PM
finance.yahoo.com logoEnanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2017
finance.yahoo.com - July 25 at 6:33 PM
americanbankingnews.com logo Analysts Anticipate Enanta Pharmaceuticals, Inc. (ENTA) Will Post Quarterly Sales of $8.12 Million
www.americanbankingnews.com - July 16 at 10:48 AM
finance.yahoo.com logoETFs with exposure to Enanta Pharmaceuticals, Inc. : July 11, 2017
finance.yahoo.com - July 11 at 7:28 PM
americanbankingnews.com logoEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 11 at 12:40 PM
prnewswire.com logoNovus Therapeutics Announces Change in Management
www.prnewswire.com - July 11 at 4:18 AM
seekingalpha.com logoEnanta To Retain Momentum On The Back Of Upcoming FDA Decision
seekingalpha.com - July 11 at 4:18 AM
streetinsider.com logoEnanta Pharma (ENTA) Presents New Data on EDP-938
www.streetinsider.com - June 27 at 5:17 PM
streetinsider.com logoEnanta Pharma (ENTA) Announces AbbVie (ABBV) Receives CHMP Positive Opinion for MAVIRET to Treat Chronic Hepatitis C in All Major Genotypes
www.streetinsider.com - June 23 at 10:38 PM
baystreet.ca logoInvestor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call
www.baystreet.ca - May 8 at 4:50 PM
businesswire.com logoEnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2017
www.businesswire.com - May 8 at 4:50 PM
marketbeat.com logoEnanta Pharmaceuticals reports 2Q loss
marketbeat.com - May 8 at 4:13 PM
businesswire.com logoEnanta Announces Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-Free HCV Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR Rates ...
www.businesswire.com - April 21 at 11:59 AM

Social

Chart

Enanta Pharmaceuticals (ENTA) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.